Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br By not conducting a

    2020-08-28


    By not conducting a separate analysis for HIV, we potentially un-derestimated the impact of infections on cancer incidence. The pro-portion of cancer attributable to EBV has the potential to increase since non-Hodgkin lymphomas among HIV positive populations were not included in this analysis.
    5. Conclusion
    We estimated that 3.7% of cancers diagnosed among Canadians aged 18 and older in 2015 were attributable to seven carcinogenic  Preventive Medicine 122 (2019) 109–117
    infections. This percentage translated into 7097 cancers, where ~6400 could potentially be prevented with currently available vaccines or treatments. HPV was responsible for more cancers than other infec-tions, comprising more than half of the infection-associated cancer burden. The presence of three vaccines that confer 95% efficacy against the HPV types responsible for cancer incidence is encouraging (Kash et al., 2015). Although Canada has a lower infection-associated cancer burden relative to many other countries (Plummer et al., 2016), in-fection-associated cancers continue to impact cancer incidence and increasing vaccine hesitancy has the potential to limit the progress that could be made in reducing the HPV and HBV associated cancer burden.
    Acknowledgements
    Karena D. Volesky is supported by a doctoral award from the Fonds de recherche du Quebec - Santé and the Fondation des étoiles. Darren Brenner holds a Canadian Cancer Society Prevention Capacity Development Award (#703917). Christine Friedenreich was supported by an Alberta Innovates Health Senior Scholar Award and by the Alberta Cancer Foundation Weekend to End Women's Cancers Breast Cancer Chair. We thank Shemay Lee for assisting us with data management.
    Competing interests
    None.
    Disclosure
    E.L.F. has served as occasional consultant to companies involved with HPV diagnostics and trans-Oxyresveratrol (Merck, GSK, Roche, and BD). His institution has received grants from Merck and Roche to supple-ment investigator-initiated studies that he leads at McGill University. E.L.F. is Editor-in-Chief at Preventive Medicine and K.D.V. is an Assistant Editor at Preventive Medicine. The process of soliciting the special issue, sending out manuscripts for review, the peer-review process and editorial decision making was conducted entirely outside of the Preventive Medicine online system (for which E.L.F. and K.D.V. have access to through their regular Preventive Medicine duties).
    Funding sources
    This research is supported by the Canadian Cancer Society Partner Prevention Research Grant (grant #703106).
    Role of funding source
    The sponsor had no role in the study design, data collection, ana-lysis or interpretation of the data, writing of the manuscript or in the decision to submit this manuscript for publication.
    Appendix A. Supplementary data
    References
    Brenner, D.R., Poirier, A.E., Walter, S.D., King, W.D., Franco, E.L., Demers, P.A., et al., 2018. Estimating the current and future cancer burden in Canada: methodological framework of the Canadian population attributable risk of cancer (ComPARe) study. BMJ Open 8 (7).
    2019. The Burden of Cancer Attributable to Modifiable Risk Factors in Canada:
    Bruni, L.B.-R.L., Albero, G., Serrano, B., Mena, M., Gómez, D., Muñoz, J., Bosch, F.X., de Sanjosé, S., 2017b. Human Papillomavirus and Related Diseases in Canada. ICO/ IARC Information Centre on HPV and Cancer (HPV Information Centre). Canadian Cancer Society's Advisory Committee on Cancer Statistics, 2015. Canadian Cancer Statistics. (Toronto, ON).
    Centers for Disease Control and Prevention, 2001. In: Department of Health and Human Services (Ed.), NHANES 1999–2000 Laboratory Data.
    Centers for Disease Control and Prevention, 2009. In: Department of Health and Human Services (Ed.), NHANES 2007–2008 Laboratory Data.
    Centers for Disease Control and Prevention, 2011. In: Department of Health and Human Services (Ed.), NHANES 2009–2010 Laboratory Data.
    Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J.
    El-Serag, H.B., 2012. Epidemiology of viral hepatitis and hepatocellular carcinoma.
    Franco, E.L., 1992. Measurement errors in epidemiological studies of human pa-pillaomvirus and cervical cancer. In: Muñoz, N.B., F.X., Meheus, A. (Eds.), The Epidemiology of Human Papillomavirus and Cervical Cancer. International Agency for Reseach on Cancer, Lyon, pp. 119.
    Gulley, M.L., Tang, W., 2008. Laboratory assays for Epstein-Barr virus-related disease. J.
    Helicobacter and Cancer Collaborative Group, 2001. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested trans-Oxyresveratrol within prospective co-horts. Gut. 49 (3), 347–353.